Current Use of Hearts From Hepatitis C Viremic Donors
Authors:
- 1 December 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 11 (12) , e005276
Abstract
Background: Strategies to improve donor heart utilization are required in the setting of limited donor availability. One innovative strategy is to consider the use of hepatitis C viremic (HCV) nucleic acid amplification test positive donors in hepatitis C-negative recipients, given the availability of highly effective direct acting antiviral agents. We utilized United Network for Organ Sharing data to evaluate the geographic distribution, clinical characteristics, and post-transplant outcomes of HCV+ donor hearts. Methods and Results: The United Network for Organ Sharing registry was queried for all HCV+ recovered donors and those considered for heart donation classified by sex, age group, United Network for Organ Sharing region, and cause of death from January 1, 2014, to December 31, 2017. Propensity score matching (3:1) was applied to the recipients based on the index for mortality prediction after cardiac transplantation score and donor risk index. A total of 1306 HCV+ donors were recovered from 2014 to 2017 of whom 1078 (82.5%) were 18 to 49 and predominantly from the Appalachia region (United Network for Organ Sharing regions 2, 3, and 11). A total of 64 (5%) HCV+ donor hearts were transplanted in this interval. The match-adjusted risk difference in survival was estimated to be 0.87% ( P =0.83) at 12 months. Conclusions: To meet the demands of heart transplantation, we must consider additional strategies to expand the donor pool. From 2014 to 2017, despite availability of highly effective direct acting antiviral therapy, only 5% of HCV+ donor hearts were accepted for transplantation. National efforts may be required to capitalize on this resource while we continue to carefully monitor the safety of this novel approach.Keywords
This publication has 11 references indexed in Scilit:
- Accepting hepatitis C virus–infected donor hearts for transplantation: Multistep consent, unrealized opportunity, and the Stanford experienceClinical Transplantation, 2018
- Early outcomes using hepatitis C–positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapiesThe Journal of Heart and Lung Transplantation, 2018
- The Drug-Intoxication Epidemic and Solid-Organ TransplantationNew England Journal of Medicine, 2018
- Increasing access to thoracic organs from donors infected with hepatitis C: A previous challenge—now an opportunityThe Journal of Heart and Lung Transplantation, 2018
- The rise of the opioid epidemic and hepatitis C–positive organs: A new era in liver transplantationHepatology, 2018
- OPTN/SRTR 2016 Annual Data Report: HeartAmerican Journal of Transplantation, 2018
- The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report—2017; Focus Theme: Allograft ischemic timeThe Journal of Heart and Lung Transplantation, 2017
- The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ TransplantationAmerican Journal of Transplantation, 2017
- Development of a quantitative donor risk index to predict short-term mortality in orthotopic heart transplantationThe Journal of Heart and Lung Transplantation, 2012
- Creation of a Quantitative Recipient Risk Index for Mortality Prediction After Cardiac Transplantation (IMPACT)The Annals of Thoracic Surgery, 2011